Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW402 in Moderate-to-Severe Active Rheumatoid Arthritis
CTR20222944Phase 2Completed
- Sponsor
- Shanghai Changsen Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing LW402 with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28-CRP at Week 12. Started Nov 2022; status: completed.
02
Drugs
lw402
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20222944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222944.